Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study

Abstract Background: Annexins are a group of conserved proteins which exert several regulatory functions on various cellular activities. Increased frequency and levels of antibodies against annexin V have already been observed in several autoimmune diseases including systemic sclerosis (SSc), but their role as a vascular biomarker is unknown. The aim of this study was to determine the serum levels and the dynamical behavior of anti-annexin V antibodies over a 24 months follow-up in patients with SSc. Methods: In this bicentric cross-sectional study, 70 patients with SSc were consecutively selected from March 2016 to April 2017. Demographic and clinical features, including the presence of active DUs, were collected. Serum anti-annexin V IgG and IgM antibodies were measured at baseline and after 6, 12 and 24 months of follow-up. Videocapillaroscopy was performed in all patients. Results: Among the 70 SSc patients included anti-annexin V IgG was found in 11 patients (15.7%) (range of 15.88–39.48 U/mL) and anti-annexin V IgM in 10 patients (14.3%) (range of 14.16-22.69 U/mL) at baseline. During follow-up, the number of patients who were positive for anti-annexin V IgG and IgM remained stable over 24 months. Among the patients with positive anti-annexin V IgG at baseline the frequency of patients with necrosis or amputation of extremities, forced vital capacity less than 70% and pulmonary arterial hypertension (PAH) was significantly higher than in patients with negative anti-annexin V IgG antibodies. Patients with anti-annexin V IgG had also a higher Raynaud's Condition Score and a higher Health Assessment Questionnaire Disability Index (HAQ-DI) than patients without these antibodies at baseline. Patients with positive anti-annexin V IgM at baseline presented a higher frequency of PAH, compared to those with negative anti-annexin V IgM at baseline. Conclusions: Anti-annexin V antibodies are stable and do not change their positivity during a 24 month follow-up in SSc patients. Anti-annexin V IgG was associated with more severe interstitial lung involvement and digital microangiopathy, and patients with anti-annexin V IgG or IgM had a higher occurrence of PAH indicating an association of these biomarker with more severe disease.

Saved in:
Bibliographic Details
Main Authors: Horimoto,Alex Magno Coelho, Jesus,Laize Guerreiro de, Souza,Albert Schiaveto de, Rodrigues,Silvia Helena, Kayser,Cristiane
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Reumatologia 2020
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2523-31062020000100231
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S2523-31062020000100231
record_format ojs
spelling oai:scielo:S2523-310620200001002312020-08-05Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal studyHorimoto,Alex Magno CoelhoJesus,Laize Guerreiro deSouza,Albert Schiaveto deRodrigues,Silvia HelenaKayser,Cristiane Systemic sclerosis Anti-annexin V Digital ulcers Vasculopathy Biomarkers Abstract Background: Annexins are a group of conserved proteins which exert several regulatory functions on various cellular activities. Increased frequency and levels of antibodies against annexin V have already been observed in several autoimmune diseases including systemic sclerosis (SSc), but their role as a vascular biomarker is unknown. The aim of this study was to determine the serum levels and the dynamical behavior of anti-annexin V antibodies over a 24 months follow-up in patients with SSc. Methods: In this bicentric cross-sectional study, 70 patients with SSc were consecutively selected from March 2016 to April 2017. Demographic and clinical features, including the presence of active DUs, were collected. Serum anti-annexin V IgG and IgM antibodies were measured at baseline and after 6, 12 and 24 months of follow-up. Videocapillaroscopy was performed in all patients. Results: Among the 70 SSc patients included anti-annexin V IgG was found in 11 patients (15.7%) (range of 15.88–39.48 U/mL) and anti-annexin V IgM in 10 patients (14.3%) (range of 14.16-22.69 U/mL) at baseline. During follow-up, the number of patients who were positive for anti-annexin V IgG and IgM remained stable over 24 months. Among the patients with positive anti-annexin V IgG at baseline the frequency of patients with necrosis or amputation of extremities, forced vital capacity less than 70% and pulmonary arterial hypertension (PAH) was significantly higher than in patients with negative anti-annexin V IgG antibodies. Patients with anti-annexin V IgG had also a higher Raynaud's Condition Score and a higher Health Assessment Questionnaire Disability Index (HAQ-DI) than patients without these antibodies at baseline. Patients with positive anti-annexin V IgM at baseline presented a higher frequency of PAH, compared to those with negative anti-annexin V IgM at baseline. Conclusions: Anti-annexin V antibodies are stable and do not change their positivity during a 24 month follow-up in SSc patients. Anti-annexin V IgG was associated with more severe interstitial lung involvement and digital microangiopathy, and patients with anti-annexin V IgG or IgM had a higher occurrence of PAH indicating an association of these biomarker with more severe disease.info:eu-repo/semantics/openAccessSociedade Brasileira de ReumatologiaAdvances in Rheumatology v.60 20202020-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2523-31062020000100231en10.1186/s42358-020-00140-w
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Horimoto,Alex Magno Coelho
Jesus,Laize Guerreiro de
Souza,Albert Schiaveto de
Rodrigues,Silvia Helena
Kayser,Cristiane
spellingShingle Horimoto,Alex Magno Coelho
Jesus,Laize Guerreiro de
Souza,Albert Schiaveto de
Rodrigues,Silvia Helena
Kayser,Cristiane
Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study
author_facet Horimoto,Alex Magno Coelho
Jesus,Laize Guerreiro de
Souza,Albert Schiaveto de
Rodrigues,Silvia Helena
Kayser,Cristiane
author_sort Horimoto,Alex Magno Coelho
title Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study
title_short Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study
title_full Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study
title_fullStr Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study
title_full_unstemmed Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study
title_sort anti-annexin v autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study
description Abstract Background: Annexins are a group of conserved proteins which exert several regulatory functions on various cellular activities. Increased frequency and levels of antibodies against annexin V have already been observed in several autoimmune diseases including systemic sclerosis (SSc), but their role as a vascular biomarker is unknown. The aim of this study was to determine the serum levels and the dynamical behavior of anti-annexin V antibodies over a 24 months follow-up in patients with SSc. Methods: In this bicentric cross-sectional study, 70 patients with SSc were consecutively selected from March 2016 to April 2017. Demographic and clinical features, including the presence of active DUs, were collected. Serum anti-annexin V IgG and IgM antibodies were measured at baseline and after 6, 12 and 24 months of follow-up. Videocapillaroscopy was performed in all patients. Results: Among the 70 SSc patients included anti-annexin V IgG was found in 11 patients (15.7%) (range of 15.88–39.48 U/mL) and anti-annexin V IgM in 10 patients (14.3%) (range of 14.16-22.69 U/mL) at baseline. During follow-up, the number of patients who were positive for anti-annexin V IgG and IgM remained stable over 24 months. Among the patients with positive anti-annexin V IgG at baseline the frequency of patients with necrosis or amputation of extremities, forced vital capacity less than 70% and pulmonary arterial hypertension (PAH) was significantly higher than in patients with negative anti-annexin V IgG antibodies. Patients with anti-annexin V IgG had also a higher Raynaud's Condition Score and a higher Health Assessment Questionnaire Disability Index (HAQ-DI) than patients without these antibodies at baseline. Patients with positive anti-annexin V IgM at baseline presented a higher frequency of PAH, compared to those with negative anti-annexin V IgM at baseline. Conclusions: Anti-annexin V antibodies are stable and do not change their positivity during a 24 month follow-up in SSc patients. Anti-annexin V IgG was associated with more severe interstitial lung involvement and digital microangiopathy, and patients with anti-annexin V IgG or IgM had a higher occurrence of PAH indicating an association of these biomarker with more severe disease.
publisher Sociedade Brasileira de Reumatologia
publishDate 2020
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2523-31062020000100231
work_keys_str_mv AT horimotoalexmagnocoelho antiannexinvautoantibodiesandvascularabnormalitiesinsystemicsclerosisalongitudinalstudy
AT jesuslaizeguerreirode antiannexinvautoantibodiesandvascularabnormalitiesinsystemicsclerosisalongitudinalstudy
AT souzaalbertschiavetode antiannexinvautoantibodiesandvascularabnormalitiesinsystemicsclerosisalongitudinalstudy
AT rodriguessilviahelena antiannexinvautoantibodiesandvascularabnormalitiesinsystemicsclerosisalongitudinalstudy
AT kaysercristiane antiannexinvautoantibodiesandvascularabnormalitiesinsystemicsclerosisalongitudinalstudy
_version_ 1756441906741510144